Abrupt Discontinuation of Psychotropic Drugs Following Confirmation of Pregnancy: A Risky Practice

Journal of Obstetrics and Gynaecology Canada

Volumn 27, Issue 11, 2005, Pages 1019-1022

  Einarson, Adrienne ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Mental health; Pregnancy; Psychosis; Psychotropic drugs; Teratogens

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; PAROXETINE; TERATOGENIC AGENT;

ARTICLE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; PATIENT ATTITUDE; PATIENT COUNSELING; PATIENT INFORMATION; PREGNANCY; RISK ASSESSMENT; ADULT; CASE REPORT; CHEMICALLY INDUCED DISORDER; COUNSELING; FEMALE; MENTAL DISEASE; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION; PUERPERAL DEPRESSION; RISK FACTOR; WITHDRAWAL SYNDROME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COUNSELING; DEPRESSION, POSTPARTUM; FEMALE; HUMANS; MENTAL DISORDERS; PAROXETINE; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS; RISK FACTORS; SUBSTANCE WITHDRAWAL SYNDROME; TERATOGENS;

EID: 33646336901     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)30500-X     Document Type: Article

References (36)

1. Cott AD, Wisner KL Psychiatric disorders during pregnancy. Int Rev Psychiatry 2003, 15(3):217-230.
2. Kalra S, Born L, Sarkar M, Einarson A The safety of antidepressant use in pregnancy. Expert Opin Drug Saf 2005, 4(2):273-284.
3. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002, 159(11):1889-1895.
4. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998, 317(7162):839-843.
5. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. Am J Obstet Gynecol 1977, 128(5):486-488.
6. Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbis H, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry 2005, 66(3):317-322.
7. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005, 66(4):444-449.
8. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 999;57(4):535-44.
9. Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64(6):961-965.
10. Cunnington M, Tennis P Lamotrigine and the risk of malformations in pregnancy. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Neurology 2005, 64(6):955-960.
11. Montouris G Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 2005, 21(5):693-701.
12. Montouris G Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003, 4(3):310-317.
13. Linden S, Rich CL The use of lithium during pregnancy and lactation. J Clin Psychiatry 1983, 44(10):358-361.
14. Jacobson SJ, Jones K, Johnson K, Ceolin L, Kaur P, Sahn D, et al. Prospective multicentre study of pregnancy outcome after lithium exposure. during first trimester. Lancet 1992, 339(8792):530-533.
15. Gracious BL, Wisner KL Phenelzine use throughout pregnancy and the Puerperium: case report, review of the literature, and management recommendations. Depress Anxiety 1997, 6(3):124-128.
16. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S Birth defects and drugs in pregnancy 1977, 336-337. Publishing Sciences Group, Littleton.
17. Rybakowski JK Moclobemide in pregnancy. Pharmacopsychiatry 2001, 34(2):82-83.
18. Bonari L, Koren G, Einarson TR, Jasper JD, Einarson A. Use of antidepressants by pregnant women: Evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making. Arch Women Ment Health 2005; Jun 17.
19. Allison SK Psychotropic medication in pregnancy: ethical aspects and clinical management. J Perināt Neonatal Nurs 2004, 18(3):194-205.
20. Rosabaum ZJ Clinical management of antidepressant discontinuation. J Clin Psychiatry 1997, 58(7):37-40.
21. Kaplan EM Antidepressant noncompliance as a factor in the discontinuation syndrome. J Clin Psychiatry 1997, 58(7):31-35.
22. Einarson A, Selby P, Koren G Abrupt discontinuation of psychotropic drugs due to fears of teratogenic risk and the impact of counseling. J Psychiatry Neurosci 2001, 26(1):44-48.
23. Rickels K, Case WG, Schweitzer E Benzodiazepine dependence: management of discontinuation. Psychopharmacol Bull 1990, 26(l):63-68.
24. Turkington D, Gill P Mania induced by lorazepam withdrawal: two case reports. J Affect Dis 1989, 17(1):93-95.
25. Haque W, Watson DJ, Bryant SG Death following suspected alprazolam withdrawal seizures: a case report. Tex Med 1990, 86(1):44-47.
26. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Clin Psychiatry 2000, 61(11):833-840.
27. Viguera AC, Baldessarini RJ, Hegarty JD, van Kämmen DP, Tohen M Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997, 54(l):49-55.
28. Sabers A, Gram L Newer anticonvulsants: comparative review of drug interaction and adverse effects. Drugs 2000, 60(1):23-33.
29. Heh CW, Sramek J, Herrera J, Costa J Exacerbation of psychosis after discontinuation of carbamazepine treatment. Am J Psychiatry 1988, 145(7):878-879.
30. Kenneback G, Ericson M, Tomson T Bergfeldt L. Changes in arrhythmia profile and heart rate variability during abrupt withdrawal of antiepileptic drugs. Implications for sudden death. Seizure 1997, 6(5):369-375.
31. Baldessarini RJ, Suppes T, Tondo L Lithium withdrawal in bipolar disorder: implications for clinical practice and experimental therapeutics research. Am J Ther 1996, 3(7):492-496.
32. Christodoulou GN, Lykouras EP Abrupt lithium discontinuation in manic-depressive patients. Acta Psychiatr Scand 1982, 65(5):310-314.
33. Swartz CM, Dolinar LJ Encephalopathy associated with rapid decrease of high levels of lithium. Ann Clin Psychiatry 1995, 7(4):207-209.
34. Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000, 157(2):179-184.
35. Dilsaver SC Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Prog Neuropsychopharmacol Biol Psychiatry 1990, 14(2):137-161.
36. Halle MT, Dilsaver SC Tranylcypromine withdrawal phenomena. J Psychiatry Neurosci 1993, 18(1):49-50.